Johnson & Johnson 4Q Revenues: $15.2 billion (-5%) 4Q Earnings: $2.7 billion (+13%) FY Revenues: $63.7 billion (+4%) FY Earnings: $12.9 billion (+22%) Comments: Pharmaceutical sales were $5.7 billion in the quarter (-11%) and $24.6 billion for the year (-1%). Domestic sales were down 5%, while international sales increased 5% (0.1% from operations and 5% from currency). Velcade sales were $208 million in the quarter (+26%) and $787 million for the year (+47%). Risperdal Consta...